|
1
|
Nault JC, Bioulac-Sage P and Zucman-Rossi
J: Hepatocellular benign tumors-from molecular classification to
personalized clinical care. Gastroenterology. 144:888–902. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bioulac-Sage P, Balabaud C and
Zucman-Rossi J: Focal nodular hyperplasia, hepatocellular adenomas:
Past, present, future. Gastroenterol Clin Biol. 34:355–358. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Aalten SM, Witjes CD, de Man RA,
Ijzermans JN and Terkivatan T: Can a decision-making model be
justified in the management of hepatocellular adenoma? Liver Int.
32:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi BY and Nguyen MH: The diagnosis and
management of benign hepatic tumors. J Clin Gastroenterol.
39:401–412. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Buell JF, Tranchart H, Cannon R and Dagher
I: Management of benign hepatic tumors. Surg Clin North Am.
90:719–735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bioulac-Sage P, Laumonier H, Couchy G, Le
Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G,
Trillaud H, et al: Hepatocellular adenoma management and phenotypic
classification: The Bordeaux experience. Hepatology. 50:481–489.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Micchelli ST, Vivekanandan P, Boitnott JK,
Pawlik TM, Choti MA and Torbenson M: Malignant transformation of
hepatic adenomas. Mod Pathol. 21:491–497. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zucman-Rossi J, Jeannot E, Nhieu JT,
Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis
V, Michalak S, et al: Genotype-phenotype correlation in
hepatocellular adenoma: New classification and relationship with
HCC. Hepatology. 43:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shanbhogue A, Shah SN, Zaheer A, Prasad
SR, Takahashi N and Vikram R: Hepatocellular adenomas: Current
update on genetics, taxonomy, and management. J Comput Assist
Tomogr. 35:159–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Velazquez I and Alter BP: Androgens and
liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J
Hematol. 77:257–267. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carrasco D, Barrachina M, Prieto M and
Berenguer J: Clomiphene citrate and liver-cell adenoma. N Engl J
Med. 310:1120–1121. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vazquez JJ and Marigil MA: Liver-cell
adenoma in an epileptic man on barbiturates. Histol Histopathol.
4:301–303. 1989.PubMed/NCBI
|
|
13
|
Espat J, Chamberlain RS, Sklar C and
Blumgart LH: Hepatic adenoma associated with recombinant human
growth hormone therapy in a patient with Turner's syndrome. Dig
Surg. 17:640–643. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bioulac-Sage P, Rebouissou S, Thomas C,
Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G,
Imbeaud S, et al: Hepatocellular adenoma subtype classification
using molecular markers and immunohistochemistry. Hepatology.
46:740–748. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manichon AF, Bancel B, Durieux-Millon M,
Ducerf C, Mabrut JY, Lepogam MA and Rode A: Hepatocellular adenoma:
Evaluation with contrast-enhanced ultrasound and MRI and
correlation with pathologic and phenotypic classification in 26
lesions. HPB Surg. 2012:4187452012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bluteau O, Jeannot E, Bioulac-Sage P,
Marqués JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C,
Laurent-Puig P and Zucman-Rossi J: Bi-allelic inactivation of TCF1
in hepatic adenomas. Nat Genet. 32:312–315. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pelletier L, Rebouissou S, Paris A,
Rathahao-Paris E, Perdu E, Bioulac-Sage P, Imbeaud S and
Zucman-Rossi J: Loss of hepatocyte nuclear factor 1alpha function
in human hepatocellular adenomas leads to aberrant activation of
signaling pathways involved in tumorigenesis. Hepatology.
51:557–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Antequera F and Bird A: Number of CpG
islands and genes in human and mouse. Proc Natl Acad Sci USA.
90:11995–11999. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome-biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung
G and Park YN: Aberrant CpG island hypermethylation in dysplastic
nodules and early HCC of hepatitis B virus-related human multistep
hepatocarcinogenesis. J Hepatol. 54:939–947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pogribny IP and Rusyn I: Role of
epigenetic aberrations in the development and progression of human
hepatocellular carcinoma. Cancer Lett. 342:223–230. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki MM and Bird A: DNA methylation
landscapes: Provocative insights from epigenomics. Nat Rev Genet.
9:465–476. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP
and Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA
methylation to histone methylation. J Biol Chem. 278:4035–4040.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim BH, Cho NY, Shin SH, Kwon HJ, Jang JJ
and Kang GH: CpG island hypermethylation and repetitive DNA
hypomethylation in premalignant lesion of extrahepatic
cholangiocarcinoma. Virchows Arch. 455:343–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang YJ, Wu HC, Yazici H, Yu MW, Lee PH
and Santella RM: Global hypomethylation in hepatocellular carcinoma
and its relationship to aflatoxin B(1) exposure. World J Hepatol.
4:169–175. 2012. View Article : Google Scholar PubMed/NCBI
|
|
26
|
Tangkijvanich P, Hourpai N, Rattanatanyong
P, Wisedopas N, Mahachai V and Mutirangura A: Serum LINE-1
hypomethylation as a potential prognostic marker for hepatocellular
carcinoma. Clin Chim Acta. 379:127–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ
and Santella RM: Global DNA methylation levels in white blood cells
as a biomarker for hepatocellular carcinoma risk: A nested
case-control study. Carcinogenesis. 33:1340–1345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Graziadei I, Finkenstedt A, Stauber RE,
Müller C, Trauner M and Vogel W: 78 Imatinib treatment for patients
with advanced stage hepatocellular carcinoma: A multicenter phase
II trial. Gastroenterology. 138:(Suppl 1). S775–S776. 2010.
View Article : Google Scholar
|
|
29
|
Pilati C, Letouzé E, Nault JC, Imbeaud S,
Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette
G, et al: Genomic profiling of hepatocellular adenomas reveals
recurrent FRK-activating mutations and the mechanisms of malignant
transformation. Cancer Cell. 25:428–441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
You JS and Jones PA: Cancer genetics and
epigenetics: Two sides of the same coin? Cancer cell. 22:9–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Anwar SL and Lehmann U: DNA methylation,
microRNAs, and their crosstalk as potential biomarkers in
hepatocellular carcinoma. World J Gastroenterol. 20:7894–7913.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Knudson AG: Cancer genetics. Am J Med
Genet. 111:96–102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rodriguez-Paredes M and Esteller M: Cancer
epigenetics reaches mainstream oncology. Nat Med. 17:330–339. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cedar H and Bergman Y: Programming of DNA
methylation patterns. Annu Rev Biochem. 81:97–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee HS, Kim BH, Cho NY, Yoo EJ, Choi M,
Shin SH, Jang JJ, Suh KS, Kim YS and Kang GH: Prognostic
implications of and relationship between CpG island
hypermethylation and repetitive DNA hypomethylation in
hepatocellular carcinoma. Clin Cancer Res. 15:812–820. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park HJ, Yu E and Shim YH: DNA
methyltransferase expression and DNA hypermethylation in human
hepatocellular carcinoma. Cancer Lett. 233:271–278. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Csepregi A, Röcken C, Hoffmann J, Gu P,
Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A,
Malfertheiner P and Ebert MP: APC promoter methylation and protein
expression in hepatocellular carcinoma. J Cancer Res Clin Oncol.
134:579–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lehmann U, Berg-Ribbe I, Wingen LU,
Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H
and Flemming P: Distinct methylation patterns of benign and
malignant liver tumors revealed by quantitative methylation
profiling. Clin Cancer Res. 11:3654–3660. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, Du X
and Huang ZH: Quantitative methylation analysis of multiple genes
using methylation-sensitive restriction enzyme-based quantitative
PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol.
91:455–460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang L, Wang WL, Zhang Y, Guo SP, Zhang J
and Li QL: Epigenetic and genetic alterations of PTEN in
hepatocellular carcinoma. Hepatol Res. 37:389–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ and
Kang GH: Aberrant CpG island hypermethylation along multistep
hepatocarcinogenesis. Am J Pathol. 163:1371–1378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nishida N, Kudo M, Nagasaka T, Ikai I and
Goel A: Characteristic patterns of altered DNA methylation predict
emergence of human hepatocellular carcinoma. Hepatology.
56:994–1003. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shim YH, Yoon GS, Choi HJ, Chung YH and Yu
E: p16 Hypermethylation in the early stage of hepatitis B
virus-associated hepatocarcinogenesis. Cancer Lett. 190:213–219.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Boas FE, Do B, Louie JD, Kothary N, Hwang
GL, Kuo WT, Hovsepian DM, Kantrowitz M and Sze DY: Optimal imaging
surveillance schedules after liver-directed therapy for
hepatocellular carcinoma. J Vasc Interv Radiol. 26:69–73. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kong WT, Wang WP, Huang BJ, Ding H, Mao F
and Si Q: Contrast-enhanced ultrasound in combination with color
doppler ultrasound can improve the diagnostic performance of focal
nodular hyperplasia and hepatocellular adenoma. Ultrasound Med
Biol. 41:944–951. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Christensen U, Simonsen M, Harrit N and
Sottrup-Jensen L: Pregnancy zone protein, a proteinase-binding
macroglobulin. Interactions with proteinases and methylamine.
Biochemistry. 28:9324–9331. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Berne BH: Alpha-2 pregnoglobulin
(pregnancy zone protein)-An estrogen-dependent macroglobulin
elevated in pregnancy and oral contraception. Clin Chem.
19:6571973.
|
|
48
|
Boxberger KH, Hagenbuch B and Lampe JN:
Common drugs inhibit human organic cation transporter 1
(OCT1)-mediated neurotransmitter uptake. Drug Metab Dispos.
42:990–995. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Thomas DP and Vane JR: 5-hydroxytryptamine
in the circulation of the dog. Nature. 216:335–338. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cao C, Li X, Liu T, Zhang L, Shen K and
Zhu H: Human organic cation transporter 1 protein levels of
granulocytes can optimize imatinib therapy in patients with chronic
myeloid leukemia. Acta Haematol. 133:199–204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Loeb LA and Harris CC: Advances in
chemical carcinogenesis: A historical review and prospective.
Cancer Res. 68:6863–6872. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fraga MF, Herranz M, Espada J, Ballestar
E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, et
al: A mouse skin multistage carcinogenesis model reflects the
aberrant DNA methylation patterns of human tumors. Cancer Res.
64:5527–5534. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yamamoto E, Yamano HO, Suzuki H, Kamimae
S, Imai K, Shinomura Y and Toyota M: The role of aberrant DNA
methylation in carcinogenesis of colorectal tumor with K-ras
mutation. Japan J Mol Tumor Marker Res. 25:37–38. 2010.(In
Japanese).
|
|
54
|
Pogribny IP and Rusyn I: Environmental
toxicants, epigenetics, and cancer. Adv Exp Med Biol. 754:215–232.
2013. View Article : Google Scholar : PubMed/NCBI
|
